Division of Bristol-Myers Squibb Co.
Latest From Delinia Inc.
Celgene has hit multiple roadblocks in building its inflammation and immunology (I&I) portfolio, but it has a lot of potential shots on goal to eventually help the company diversify its revenue beyond the cancer blockbuster Revlimid, starting with flagship product Otezla.
Celgene, which continues to plough back a very high proportion of its revenues into R&D, remains the preferred partner of choice for biotechs who hope to bring the next wave of innovative products to the market, Kevin Loth, VP of corporate affairs and policy in Europe tells Scrip.
Since becoming CEO of TxCell two years ago, Stéphane Boissel has reorganized the R&D plan, restructured and reduced the head count and put the company on the road to scalable manufacturing of CAR-T regulatory cells. And he has put strategic partnerships on the agenda. It is a big change from the situation 12 months ago, he told In Vivo during the Annual European Advanced Therapies Investor Day.
This week's roundup includes CEO appointments by Gadeta, Scancell and Zafgen, with various other high-level appointments by Malin Corporation, Cell Medica and Apeiron Biologics.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- North America
- Company Type
- Parent & Subsidiaries
- Bristol-Myers Squibb Co.
- Senior Management
Saurabh Saha, MD, PhD, Pres. & CEO
Jeffrey Greve, PhD, CSO
- Contact Info
5980 Horton St.
Emeryville, CA 94608
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.